Listed by the USPTO as MARVICH, MARIA
Tech Center 1600 • Art Units: 1631 1633 1634 1645
This examiner grants 55% of resolved cases
MARVICH, MARIA is assigned to tech center 1600 and art unit 1631. Across 991 resolved cases, the allowance rate is 55.0% and the interview lift is 28.0%. The median time to allowance is 1471 days, indicating that prosecution planning should account for an extended path to disposition.
Listed companies include Massachusetts Institute of Technology, Hryz Biotech Co., and Novartis AG. Listed firms include Knobbe, Martens, Olson & Bear, LLP, Johnson, Marcou, Isaacs & Nix, LLC, and MORRISON & FOERSTER LLP. Interviews may assist, but the allowance record supports careful claim and response development.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18051936 | MINIATURIZED DYSTROPHINS HAVING SPECTRIN FUSION DOMAINS AND USES THEREOF | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Non-Final OA | Novartis AG |
| 19449304 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 17767970 | CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17768591 | COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY | Final Rejection | The Johns Hopkins University |
| 18705359 | METHOD FOR PRODUCING MILK LIKE PRODUCTS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18019423 | Molecular Targets for Modulation of Dissociative and Associative States | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18612441 | TREATMENT AGENT FOR HAIR DAMAGE | Final Rejection | TOHOKU UNIVERSITY |
| 17273688 | BASE EDITING FOR TREATING HUTCHINSON-GILFORD PROGERIA SYNDROME | Non-Final OA | President and Fellows of Harvard College |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Final Rejection | Board of Regents of The University of Texas System |
| 18050192 | Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 Immunotherapy | Non-Final OA | The Regents of the University of Colorado |
| 18268533 | MICROCARRIER FOR CELL CULTURE AND CELL CULTURE METHOD | Non-Final OA | SEKISUI CHEMICAL CO., LTD. |
| 18875094 | CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18574777 | ENGINEERED NODAVIRAL CARGO DELIVERY SYSTEMS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18031486 | Engineered Cells for Increased Collagen Production | Non-Final OA | Northeastern University |
| 18748156 | HYPOVENTILATION PHYSICAL MODELS AND APPLICATIONS THEREOF | Non-Final OA | The University of Hong Kong |
| 17904229 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | Non-Final OA | Temple University-Of The Commonwealth System of Higher Education |
| 17855322 | ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | Non-Final OA | Baylor College of Medicine |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.0% of resolved applications examined by Maria Marvich were allowed (991 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +28.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Maria Marvich took 1,471 days on average from filing to allowance.
Maria Marvich examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
